First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label,...

by Wu, Y-L, Zhou, C.., Liam, Chong-Kin, Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y., How, Soon Hin, ., et al.
Published 2015